Edwards Lifesciences’ TRISCEND II Trial: A Game-Changer in Tricuspid Valve Treatment?

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study.

Edwards Lifesciences Corp. is conducting the TRISCEND II Pivotal Trial to assess the safety and effectiveness of the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement system. This study aims to provide a novel treatment option for patients with severe tricuspid regurgitation by comparing the EVOQUE system combined with optimal medical therapy (OMT) against OMT alone.

The intervention being tested is the Edwards EVOQUE System, a device designed for transcatheter tricuspid valve replacement, intended to improve outcomes for patients with tricuspid regurgitation.

The study is a randomized, multi-center, interventional trial with a parallel assignment. It is unmasked and primarily focused on treatment efficacy.

The trial began on April 9, 2021, with an estimated completion date in 2025. The most recent update was submitted on August 13, 2025, indicating ongoing progress in the study.

This clinical update could influence Edwards Lifesciences’ stock performance positively, as successful results may enhance their market position in the cardiovascular device industry. Investors should monitor competitor developments and industry trends for a comprehensive view.

The TRISCEND II Pivotal Trial is currently active and ongoing, with further details accessible on the ClinicalTrials portal.